Century TherapeuticsIPSC
IPSC
About: Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Employees: 165
0
Funds holding %
of 7,299 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3% less funds holding
Funds holding: 72 [Q4 2024] → 70 (-2) [Q1 2025]
8.45% less ownership
Funds ownership: 42.81% [Q4 2024] → 34.36% (-8.45%) [Q1 2025]
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
45% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 29
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
62% less capital invested
Capital invested by funds: $36.8M [Q4 2024] → $14.1M (-$22.7M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
243%
upside
Avg. target
$3.33
472%
upside
High target
$6
929%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Geulah Livshits | 929%upside $6 | Buy Maintained | 16 May 2025 |
HC Wainwright & Co. Mitchell Kapoor | 243%upside $2 | Buy Maintained | 3 Apr 2025 |
Piper Sandler Edward Tenthoff | 243%upside $2 | Overweight Maintained | 20 Mar 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
GlobeNewsWire
2 weeks ago
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer.
Positive
Zacks Investment Research
1 month ago
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Negative
Zacks Investment Research
1 month ago
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer.
Positive
Zacks Investment Research
2 months ago
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Negative
Zacks Investment Research
2 months ago
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.
Neutral
GlobeNewsWire
6 months ago
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
Charts implemented using Lightweight Charts™